Molecular Genetics

FDA Approves Truqap, Faslodex for HR-Positive Breast Cancer

November 21, 2023 - On November 16, 2023, the United States Food and Drug Administration approved AstraZeneca’s Truqap (capivasertib) to be administered in combination with fulvestrant for adults with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR-positive, HER2-negative) locally advanced or metastatic breast cancer. Adding to...

Read More


More Articles

FDA Grants Bluebird Bio Priority Review of BLA for SCD Treatment

by Veronica Salib

On June 21, 2023, Bluebird Bio issued a press release announcing that the FDA had granted its biological license application (BLA) for a new sickle cell disease (SCD) treatment priority review...

Eli Lilly Acquires Akouos in Approximately $487 Million Transaction

by Veronica Salib

In a recent press release from Eli Lilly and Company, the company announced that it had completed the acquisition of Akouos. Earlier this year, on October 18, 2022, Lilly announced plans to acquire the...

Recent Articles